Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS

Robert G. Miller, Gilbert Block, Jonathan S. Katz, Richard J. Barohn, Vidhya Gopalakrishnan, Merit Cudkowicz, Jane R. Zhang, Michael S. McGrath, Elizabeth Ludington, Stanley H. Appel, Ari Azhir

Research output: Contribution to journalArticle

49 Scopus citations

Fingerprint Dive into the research topics of 'Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS'. Together they form a unique fingerprint.

Medicine & Life Sciences